Summit Therapeutics Inc.SMMTEarnings & Financial Report
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation ; nivolumab (Opdivo), used to treat certain types of cancer ; lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes ; abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid ...
Revenue
$235.0K
Gross Profit
N/A
Operating Profit
$-12.7M
Net Profit
$-16.8M
Gross Margin
N/A
Operating Margin
-5400.9%
Net Margin
-7136.6%
YoY Growth
312.3%
EPS
$-0.12
Summit Therapeutics Inc. Q2 FY2022 Financial Summary
Summit Therapeutics Inc. reported revenue of $235.0K (up 312.3% YoY) for Q2 FY2022, with a net profit of $-16.8M (up 31.3% YoY) (-7136.6% margin).
Key Financial Metrics
| Total Revenue | $235.0K |
|---|---|
| Net Profit | $-16.8M |
| Gross Margin | N/A |
| Operating Margin | -5400.9% |
| Report Period | Q2 FY2022 |
Summit Therapeutics Inc. Quarterly Revenue & Net Profit History
Summit Therapeutics Inc. results over the last 7 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2024 | $0 | — | $-56.3M | N/A |
| Q3 FY2023 | $0 | — | $-21.3M | N/A |
| Q2 FY2023 | $0 | — | $-14.7M | N/A |
| Q1 FY2023 | $0 | — | $-542.4M | N/A |
| Q3 FY2022 | $220.0K | -83.2% | $-21.4M | -9720.5% |
| Q2 FY2022 | $235.0K | +312.3% | $-16.8M | -7136.6% |
| Q1 FY2022 | $250.0K | +30.2% | $-21.4M | -8558.8% |
Income Statement
| Q1 2022 | Q2 2022 | Q3 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q3 2024 | |
|---|---|---|---|---|---|---|---|
| Revenue | $250000 | $235000 | $220000 | $0 | $0 | $0 | $0 |
| YoY Growth | 30.2% | 312.3% | -83.2% | N/A | N/A | N/A | N/A |
Balance Sheet
| Q1 2022 | Q2 2022 | Q3 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q3 2024 | |
|---|---|---|---|---|---|---|---|
| Assets | $116.5M | $95.7M | $155.3M | $254.9M | $237.4M | $218.5M | $502.9M |
| Liabilities | $52.1M | $44.4M | $22.1M | $121.4M | $117.8M | $119.1M | $64.9M |
| Equity | $64.4M | $51.3M | $133.2M | $133.5M | $119.6M | $99.4M | $437.9M |
Cash Flow
| Q1 2022 | Q2 2022 | Q3 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q3 2024 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $-19.0M | $-19.2M | $-8.6M | $-13.1M | $-29.3M | $-14.9M | $-30.3M |